POTENTIAL ANTIDEPRESSIVE PROPERTIES OF AMANTADINE, MEMANTINE AND BIFEMELANE

被引:147
作者
MORYL, E
DANYSZ, W
QUACK, G
机构
[1] MERZ & CO,ECKENHEIMER LANDSTR 100-104,W-6000 FRANKFURT,GERMANY
[2] POLISH ACAD SCI,INST PHARMACOL,PL-31343 KRAKOW,POLAND
来源
PHARMACOLOGY & TOXICOLOGY | 1993年 / 72卷 / 06期
关键词
D O I
10.1111/j.1600-0773.1993.tb01351.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of amantadine, its dimethyl derivative, memantine and the chemically unrelated compound bifemelane were tested for antidepressant activity. Reserpine-induced hypothermia and the forced swim test (Porsolt test) were selected for this purpose. In the former test amantadine and bifemelane but not memantine were effective. In the forced swim test all three agents produced antidepressive-like activity (decreased immobility time), but in case of bifemelane it was less pronounced. The effect in the forced swim test was specific i.e. it was apparently not the result of an increase in general activity as evidenced by control experiments in the open field. The mechanism of amantadine and memantine action may involve indirect dopaminomimetic activity resulting from the blockade of NMDA receptors. However in reserpine-induced hypothermia this explanation is not valid considering the lack of effect of memantine and positive action of amantadine. Hence, amantadine may have an additional central sympathomimetic action that memantine is lacking. Bifemelane antidepressant-like activity might be attributed to an enhancement of noradrenergic transmission. We suggested that amantadine and bifemelane could be particularly useful therapeutically when depressive symptoms are present in patients suffering from Parkinson's disease and dementia.
引用
收藏
页码:394 / 397
页数:4
相关论文
共 29 条
[2]  
CHANPALAY V, 1991, DEMENTIA, V2, P7
[3]  
Danysz W, 1991, BEHAV MODELS PSYCHOP, P126
[4]   EFFECTS OF 4-(ORTHO-BENZYLPHENOXY)-N-METHYLBUTYLAMINE HYDROCHLORIDE (MCI-2016) ON MONOAMINE METABOLISM IN THE RAT-BRAIN [J].
EGAWA, M ;
INOKUCHI, T ;
IDA, S ;
TOBE, A .
FOLIA PHARMACOLOGICA JAPONICA, 1983, 82 (05) :351-360
[5]   DOPAMINE AND NORADRENALINE RELEASING ACTION OF AMANTADINE IN CENTRAL AND PERIPHERAL NERVOUS SYSTEM - POSSIBLE MODE OF ACTION IN PARKINSON'S DISEASE [J].
FARNEBO, LO ;
FUXE, K ;
GOLDSTEIN, M ;
HAMBERGER, B ;
UNGERSTEDT, U .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1971, 16 (01) :27-+
[6]  
GORTELMEYER R, 1992, ARZNEIMITTEL-FORSCH, V42-2, P904
[7]   THE ETIOLOGY OF DEPRESSION IN PARKINSONS-DISEASE PATIENTS [J].
GUZE, BH ;
BARRIO, JC .
PSYCHOSOMATICS, 1991, 32 (04) :390-395
[8]  
IIDA S, 1986, PHARMACOMETRICS, V31, P179
[9]   EFFECTS OF SEVERAL CEREBROPROTECTIVE DRUGS ON NMDA CHANNEL FUNCTION - EVALUATION USING XENOPUS OOCYTES AND [H-3] MK-801 BINDING [J].
KANEKO, S ;
SUGIMURA, M ;
INOUE, T ;
SATOH, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 207 (02) :119-128
[10]   EFFECTS OF ANTIDEPRESSANTS ON THE GLUTAMATERGIC SYSTEM IN MOUSE-BRAIN [J].
KITAMURA, Y ;
ZHAO, XH ;
TAKEI, M ;
YONEMITSU, O ;
NOMURA, Y .
NEUROCHEMISTRY INTERNATIONAL, 1991, 19 (03) :247-253